News
GYRE
6.87
-2.49%
-0.18
Analysts Offer Insights on Healthcare Companies: Rezolute (RZLT), Actinium Pharmaceuticals (ATNM) and Gyre Therapeutics (GYRE)
TipRanks · 10/05 15:40
Weekly Report: what happened at GYRE last week (0928-1002)?
Weekly Report · 10/05 09:09
Weekly Report: what happened at GYRE last week (0921-0925)?
Weekly Report · 09/28 09:09
Weekly Report: what happened at GYRE last week (0914-0918)?
Weekly Report · 09/21 09:09
Weekly Report: what happened at GYRE last week (0907-0911)?
Weekly Report · 09/14 09:09
Weekly Report: what happened at GYRE last week (0831-0904)?
Weekly Report · 09/07 09:09
Gyre Therapeutics Highlights Capital-Efficient Global Development Strategy
TipRanks · 09/01 13:35
Weekly Report: what happened at GYRE last week (0824-0828)?
Weekly Report · 08/31 09:09
Gyre Therapeutics unveils capital-efficient global development strategy
TipRanks · 08/26 13:28
Weekly Report: what happened at GYRE last week (0817-0821)?
Weekly Report · 08/24 09:09
Weekly Report: what happened at GYRE last week (0810-0814)?
Weekly Report · 08/17 09:10
Analysts Are Bullish on These Healthcare Stocks: Gyre Therapeutics (GYRE), Align Tech (ALGN)
TipRanks · 08/10 13:20
Weekly Report: what happened at GYRE last week (0803-0807)?
Weekly Report · 08/10 09:09
Gyre Q2 Loss Widens As Revenue Edges Lower; Reaffirms Revenue Guidance
NASDAQ · 08/10 07:37
Thin Float, Heavy Overhang: Analyst Warns Gyre Therapeutics’ Concentrated Ownership and Pledged Shares Heighten Liquidity and Control Risks
TipRanks · 08/10 06:01
H.C. Wainwright Sticks to Its Buy Rating for Gyre Therapeutics (GYRE)
TipRanks · 08/07 15:35
Gyre Therapeutics, Inc. (GYRE) Reports Q2 Loss, Beats Revenue Estimates
NASDAQ · 08/07 12:20
Gyre Therapeutics Affirms FY2026 Sales Guidance of $100.500M-$111.000M vs $102.300M Est
Benzinga · 08/07 12:00
Gyre Therapeutics Q2 EPS $(0.12) Misses $(0.04) Estimate, Sales $29.105M Beat $26.490M Estimate
Benzinga · 08/07 11:39
Gyre Therapeutics GAAP EPS of -$0.12 misses by $0.06, revenue of $29.1M beats by $2.61M
Seeking Alpha · 08/07 11:32
More
Webull provides a variety of real-time GYRE stock news. You can receive the latest news about Gyre Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About GYRE
Gyre Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of F351 (Hydronidone) for the treatment of MASH-associated fibrosis in the United States. It is also advancing a diverse pipeline in the PRC through its controlling interest in Gyre Pharmaceuticals, including therapeutic expansions of ETUARY, and development programs for F573, and F528. F351 is a structural derivative of ETUARY. F573 is its clinical-stage product candidate for the treatment of acute/acute-on-chronic liver failure (ALF/ACLF) in Phase 2 clinical trials in the PRC. F528 is a preclinical-stage candidate targeting chronic obstructive pulmonary disease. It is focused on commercializing therapies for the treatment of pulmonary fibrosis through its two therapeutic products: ETUARY (pirfenidone) and nintedanib. It is also focused on commercializing the avatrombopag product and discovery and development of targeted protein degrader and degrader antibody conjugate therapies.